Incyte Corp(INCY)stock report

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Finance:
Market Cap:1650M; Shares Outstanding:215.4M; Short Interest: 1.85%

EPS and Sales:
https://finance.yahoo.com/quote/INCY/financials?p=INCY

Date EPS % last year % last quarter
2018.12.31 0.52 133.99% 173.68%
2019.3.31 0.48 352.63% -7.69%
2019.6.30 0.97 1840.00% 102.08%
2019.9.30 1.57 726.32% 61.86%

 

Date Sales % last year % last quarter
2018.12.31 1882M 22.50% 39.10%
2019.3.31 498M 30.23% -73.54%
2019.6.30 1028M 13.72% 106.43%
2019.9.30 1579M 16.69% 53.60%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=INCY&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/INCY/institutional-ownership/

2020.01.13:
Total institutions: 556,Decreased 1
Shares hold: 204000k shares. Reduced 1.078k
shares% hold: 94.58%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/INCY/price-targe

Leave a Reply